{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:19:43Z","timestamp":1792685983778,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.msard.2022.103863","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T12:22:21Z","timestamp":1652185341000},"page":"103863","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine"],"prefix":"10.1016","volume":"63","author":[{"given":"Livnat","family":"Brill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0968-3576","authenticated-orcid":false,"given":"Ariel","family":"Rechtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Shifrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayal","family":"Rozenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Afanasiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omri","family":"Zveik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitzan","family":"Haham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neta","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Vaknin-Dembinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.103863_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577746","article-title":"Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: up to 6 months cross-sectional study","volume":"361","author":"Achiron","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2022.103863_bib0006","doi-asserted-by":"crossref","unstructured":"Achiron, A. et\u00a0al. COVID-19 vaccination in patients with multiple sclerosis\u00a0: what we have learnt by February 2021. 1\u20137 (2021) doi:10.1177\/13524585211003476.","DOI":"10.1177\/13524585211003476"},{"key":"10.1016\/j.msard.2022.103863_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000360","article-title":"Both cladribine and alemtuzumab may effect MS via B-cell depletion","volume":"4","author":"Baker","year":"2017","journal-title":"Neurol. Neuroimmunol. NeuroInflamm."},{"key":"10.1016\/j.msard.2022.103863_bib0017","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","article-title":"Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study","volume":"398","author":"Barda","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2022.103863_bib0010","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/0140-6736(92)92826-2","article-title":"Cladribine (2-chlorodeoxyadenosine)","volume":"340","author":"Beutler","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2022.103863_bib0014","article-title":"Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis","volume":"103343","author":"Brill","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103863_bib0013","article-title":"Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies","author":"Capone","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2022.103863_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120155","article-title":"COVID-19 vaccination in patients with multiple sclerosis: safety and humoral efficacy of the third booster dose","volume":"434","author":"Dreyer-Alster","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2022.103863_bib0005","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1001\/jama.2021.19885","article-title":"Antibody titers before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged \u226560 years","volume":"326","author":"Eliakim-Raz","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2022.103863_bib0004","article-title":"Early immunogenicity and safety of the third dose of BNT162b2 messenger RNA coronavirus disease 2019 vaccine among adults older than 60 years: real-world experience","author":"Gilboa","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.msard.2022.103863_bib0002","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning immunity after the BNT162b2 vaccine in Israel","volume":"385","author":"Goldberg","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.103863_bib0019","doi-asserted-by":"crossref","DOI":"10.1177\/11795735211060118","article-title":"Humoral immune response and lymphocyte levels after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients treated with cladribine tablets","volume":"13","author":"Grothe","year":"2021","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.msard.2022.103863_bib0025","first-page":"750","article-title":"Relationship between antibody levels and SARS-Cov-2 reinfection","volume":"51","author":"Islamoglu","year":"2021","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.msard.2022.103863_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.5109","article-title":"Immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis and weak immune response after COVID-19 vaccination","author":"K\u00f6nig","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2022.103863_bib0009","doi-asserted-by":"crossref","first-page":"e783","DOI":"10.1212\/WNL.0000000000011242","article-title":"Effect of disease-modifying therapy on disability in relapsing-remitting multiple sclerosis over 15 years","volume":"96","author":"Kalincik","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103863_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103455","article-title":"Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects","volume":"58","author":"Maniscalco","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103863_bib0001","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1038\/s41467-021-26672-3","article-title":"Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine","volume":"12","author":"Mizrahi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.msard.2022.103863_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001211","article-title":"Evaluation of COVID-19 vaccination strategies with a delayed second dose","volume":"19","author":"Moghadas","year":"2021","journal-title":"PLOS Biol."},{"key":"10.1016\/j.msard.2022.103863_bib0003","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jamainternmed.2021.7382","article-title":"Odds of testing positive for SARS-CoV-2 following receipt of 3 vs 2 doses of the BNT162b2 mRNA vaccine","volume":"182","author":"Patalon","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.msard.2022.103863_bib0026","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211058298","article-title":"Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice","volume":"14","author":"Rieckmann","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2022.103863_bib0023","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans","volume":"5","author":"Seow","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.msard.2022.103863_bib0022","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(21)01642-1","article-title":"Spike-antibody waning after second dose of BNT162b2 or ChAdOx1","volume":"398","author":"Shrotri","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2022.103863_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419854986","article-title":"Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers","volume":"12","author":"Stuve","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2022.103863_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron","author":"Tarke","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.msard.2022.103863_bib0018","doi-asserted-by":"crossref","first-page":"139","DOI":"10.15585\/mmwr.mm7104e3","article-title":"Effectiveness of a third dose of mRNA vaccines against COVID-19\u2013associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance \u2014 VISION network, 10 States, August 2021","volume":"71","author":"Thompson","year":"2022","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.msard.2022.103863_bib0015","doi-asserted-by":"crossref","first-page":"e541","DOI":"10.1212\/WNL.0000000000013108","article-title":"Humoral- and T-cell\u2013specific immune responses to SARS-CoV-2 mRNA vaccination in patients with MS using different disease-modifying therapies","volume":"98","author":"Tortorella","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103863_bib0021","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1001\/jama.2021.19996","article-title":"Durability of antibody levels after vaccination with mRNA SARS-CoV-2 vaccine in individuals with or without prior infection","volume":"326","author":"Zhong","year":"2021","journal-title":"JAMA"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822003753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822003753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:03:55Z","timestamp":1761901435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822003753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":27,"alternative-id":["S2211034822003753"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103863","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103863","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103863"}}